Plasmocin™ - Mycoplasma Elimination Reagent
Elimination and Prevention of Mycoplasma Contamination in Cell Cultures
Plasmocin™ is used to cure cell lines infected by mycoplasma and related cell wall-less bacteria.
Plasmocin™ can also be used as a routine addition in liquid media to prevent mycoplasma and more generally bacterial contamination in small and large animal cell cultures.
More info on Mycoplasma eradication
Warning: InvivoGen's anti-mycoplasma products are suitable for research purposes only, and not for human or animal care.
Treat up to 25 cell lines in T75
Plasmocin™ is provided as a cell culture tested, sterile filtered yellow solution at different concentrations:
- 25 mg/ml (Plasmocin™Treatment)
- 2.5 mg/ml (Plasmocin™ Prophylactic)
In contrast to other anti-mycoplasma compounds, Plasmocin™ is active on both free mycoplasmas and intracellular forms. This advantage is conferred by one component of Plasmocin™ which is actively transported into mammalian cells. It ensures that following treatment with Plasmocin™ a cell culture is not reinfected by mycoplasmas released from intracellular compartments of infected cells.
In all animal cell lines tested to date, even at five times the working concentration, no apparent adverse effect on cellular metabolism is observed.
No resistance in liquid cultures of mycoplasmas has ever been identified in repeated experiments attempting to measure the mutation rate. Therefore, development of resistant mycoplasma strains is virtually eliminated.
Plasmocin™ is also active at low concentrations on a broad range of Gram positive and Gram negative bacteria that are otherwise resistant to the mixture of streptomycin and penicillin, and exhibits no toxicity in eukaryotic cells.
Many cell lines infected by mycoplasmas have been successfully treated with Plasmocin™, including embryonic stem cells, hybridomas and retrovirus packaging cells.
Comparison of the most common anti-mycoplasma agents[1-3]
|Product||Supplier||Treatment||Ease of use||Efficacy||Cytotoxicity||Resistance|
|Ciprobay||Bayer||12 to 20 days||+||++||+/-||+|
|MRA||ICN||1 to 2 weeks||+||++||+/-||+|
Antibiotics commonly used in cell culture are inactive on mycoplasma (e.g. penicillins and streptomycin). Three classes of antibiotics have been shown to kill mycoplasma at relatively low concentrations: tetracyclines, macrolides and quinolones. Tetracyclines and macrolides block the protein synthesis by interfering with ribosome translation, while quinolones inhibit the replication of bacterial DNA.
Several antibiotics are commercially available for the removal of mycoplasma: BM-cyclin (Roche) contains a macrolide and a tetracycline, Ciprobay (Bayer, available only with a prescription) and MRA (ICN) are both quinolones. Plasmocin™ is the only antimycoplasma reagent that combines a macrolide and a quinolone. Unlike BM-Cyclin that requires the sequential and cyclic use of 2 antibiotics, Plasmocin™ is ready-to-use and can be added to the culture medium directly. Furthermore, the 2 antibiotics in Plasmocin™ act on separate targets blocking protein synthesis and DNA replication, whereas the 2 antibiotics in BM-Cyclin are both inhibitors of protein synthesis. Therefore, Plasmocin™ is more effective in removing mycoplasma and prevents the appearance of resistant strains. In contrast to other anti-mycoplasma compounds, Plasmocin™ is active on both free mycoplasma as well as intracellular forms. This advantage is conferred by one component of Plasmocin™ which is actively transported into mammalian cells. It ensures that following treatment with Plasmocin™ a cell culture is not reinfected by mycoplasma released from intracellular compartments of infected cells. To date, no consistent and permanent alterations that affect the eukaryotic cells during and after the treatment have been detected.
1. Uphoff CC, Drexler HG., 2005. Eradication of mycoplasma contaminations. Methods Mol Biol. 290:25-34.
2. Somasundaram C. et al., 1992. Use of ciprofloxacin and BM-Cyclin in mycoplasma decontamination.In Vitro Cell Dev Biol. 28A(11-12):708-10
3. Drexler HG. et al., 1994. Treatment of mycoplasma contamination in a large panel of cell cultures. In vitro Cell Dev Biol Anim. 30A(5):344-7
1. Uphoff CC et al., 2012. Treatment of mycoplasma contamination in cell cultures with Plasmocin. J Biomed Biotechnol. 2012:267678.
2. Rongvaux A et al., 2014. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol. 32(4):364-72.
3. Baronti C. et al., 2013. Mycoplasma removal: simple curative methods for viral supernatants. J Virol Methods. 187(2):234-7
4. Deng F. et al. 2012. Generation of induced pluripotent stem cells from human Tenon's capsule fibroblasts. Mol Vis. 18:2871-81
5. Romorini L. et al, 2013. Effect of antibiotics against Mycoplasma sp. on human embryonic stem cells undifferentiated status, pluripotency, cell viability and growth. PLoS One. 8(7):e70267
Recent articles using InvivoGen Plasmocin™ - Mycoplasma Elimination Reagent
- 2016 - Nat Med., [Epub ahead of print]
Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes.
Babon JA. et al.
- 2016 - Nat Med., [Epub ahead of print]
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.
Guryanova OA. et al.
- 2016 - Am J Trop Med Hyg., [Epub ahead of print]
Isolation of Coronavirus NL63 from Blood from Children in Rural Haiti: Phylogenetic Similarities with Recent Isolates from Malaysia
Beau De Rochars VM. et al.
- 2016 - Cancer Res., 76(9):2525-39.
TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis.
Principe DR. et al.
- 2016 - Hum Gene Ther., 27(2):184-92.
Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy.
Hanoun N. et al.
|Description||Removal agent to prevent mycoplasma contamination|
|Unit Size||25 mg (10 x 1 ml)|
|Price||For price or distributor address,
please select your country